MHLW Approves MPS VI Drug Naglzayme
This article was originally published in PharmAsia News
Osaka-based Anges MG announced that mucopolysaccharidosis VI drug Naglazyme (galsulfase) received manufacturing and marketing approval by Japan's Ministry of Health, Labor and Welfare March 28, three days after it cleared MHLW's drug review panel. The ministry considers Naglazyme the only effective treatment for MPS VI. A severe and progressive genetic disease, MPS is caused by an enzyme deficiency, which leads to progressive organ system dysfunction. Naglazyme has been available in Europe and the U.S and was designated as an orphan drug last June. The NHI price listing will take place in April 18. Anges MG obtained developing and marketing rights in Japan from California-based BioMarin. (Click here for more - Japanese language
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.